By IPP Bureau - June 01, 2023

The target boundary includes biogenic land?related emissions and removals from bioenergy feedstock

By IPP Bureau - June 01, 2023

HMD had supplied 921.7 million syringes to the Government of India to facilitate over 2.2 billion Vaccination in India till date

By IPP Bureau - May 31, 2023

Synexa joins CEPI’s esteemed Central Lab Network to improve global epidemic preparedness

By IPP Bureau - May 31, 2023

The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab

By IPP Bureau - May 31, 2023

For the treatment of Superficial Femoral Artery

By IPP Bureau - May 31, 2023

With over 150 leading companies, 300+ topline brands and knowledge-led conference sessions, the event is set to make a grand return to the South

By IPP Bureau - May 31, 2023

Capnopharm’s new CapnoPen is the first PIPAC nebulizer to obtain CE marking under the new MDR regulation 2017/745

By IPP Bureau - May 30, 2023

The company reported lifetime high EBIDTA of Rs. 250 crores

By IPP Bureau - May 30, 2023

Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22

By IPP Bureau - May 30, 2023

The company has reported total income of Rs. 1682.45 crores during the period ended March 31, 2023

By IPP Bureau - May 30, 2023

The increase in revenue and profits for the year was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil.

By IPP Bureau - May 29, 2023

The PP-based top and bottom webs are manufactured in a unique coextrusion process

By IPP Bureau - May 29, 2023

Medical Device Policy is a progressive step in propelling the country towards Atmanirbharta in the heavily import dependent Medical Device Sector

By IPP Bureau - May 29, 2023

By IPP Bureau - May 29, 2023

Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239